These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 583451)

  • 1. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of food on the bioavailability of cyclandelate from commercial capsules.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
    Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical synthesis of dual-radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells.
    White DA; Heffron F; Miciak A; Middleton B; Knights S; Knight D
    Xenobiotica; 1990 Jan; 20(1):71-9. PubMed ID: 2327109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioavailability of cyclandelate from capsules in beagle dogs and dissolution rate: correlations with bioavailability in humans.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imasato Y
    J Pharmacobiodyn; 1991 Mar; 14(3):152-60. PubMed ID: 1880705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

  • 10. [New determination of cyclandelate in plasma (author's transl)].
    Andermann G; Dietz M; Mergel D
    J Pharm Belg; 1979; 34(4):233-7. PubMed ID: 501515
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 14. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography.
    Andermann G; Dietz M
    J Chromatogr; 1981 May; 223(2):365-70. PubMed ID: 7251791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of cyclandelate on cholesterol synthesis.
    Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
    Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic cerebrovascular disorders: a clinical study with cyclandelate.
    Bassi S; Albizzati MG; Sbacchi M; Frattola L
    Br J Clin Pract; 1984 Oct; 38(10):344-9. PubMed ID: 6498057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.